Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8631839 | Journal of Clinical & Translational Endocrinology | 2018 | 20 Pages |
Abstract
Along with initial hyperglycemia and eGFR, metformin Cssmin became the only parameter that influenced FBG level (Pâ¯<â¯0.05). Duration of previous metformin use should be considered in the strategy of optimizing metformin dosage. The type-2 diabetes patients with obesity are more suggested to take shorter interval of metformin administration (or possibly with sustained-release formulation) to keep Cssmin within the therapeutic range.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Vitarani D.A. Ningrum, Zullies Ikawati, Ahmad H. Sadewa, Mohammad R. Ikhsan,